vs
Side-by-side financial comparison of ADC Therapeutics SA (ADCT) and ENANTA PHARMACEUTICALS INC (ENTA). Click either name above to swap in a different company.
ADC Therapeutics SA is the larger business by last-quarter revenue ($23.1M vs $18.6M, roughly 1.2× ENANTA PHARMACEUTICALS INC). On growth, ADC Therapeutics SA posted the faster year-over-year revenue change (36.4% vs 9.8%). Over the past eight quarters, ADC Therapeutics SA's revenue compounded faster (13.7% CAGR vs 4.5%).
ADC Telecommunications, Inc. was a communications company in Eden Prairie, Minnesota, a southwest suburb of Minneapolis. It was acquired by TE Connectivity in December 2010 and ceased to exist as a separate entity. ADC products were sold by CommScope after it acquired the Broadband Network Solutions business unit from TE Connectivity in August 2015.
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
ADCT vs ENTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $18.6M |
| Net Profit | — | $-11.9M |
| Gross Margin | — | — |
| Operating Margin | -77.7% | -60.5% |
| Net Margin | — | -64.1% |
| Revenue YoY | 36.4% | 9.8% |
| Net Profit YoY | — | 46.4% |
| EPS (diluted) | $0.04 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.1M | $18.6M | ||
| Q3 25 | $15.8M | $15.1M | ||
| Q2 25 | $18.1M | $18.3M | ||
| Q1 25 | $17.4M | $14.9M | ||
| Q4 24 | $16.9M | $17.0M | ||
| Q3 24 | $18.0M | $14.6M | ||
| Q2 24 | $17.0M | $18.0M | ||
| Q1 24 | $17.8M | $17.1M |
| Q4 25 | — | $-11.9M | ||
| Q3 25 | $-41.0M | $-18.7M | ||
| Q2 25 | $-56.6M | $-18.3M | ||
| Q1 25 | $-38.6M | $-22.6M | ||
| Q4 24 | — | $-22.3M | ||
| Q3 24 | $-44.0M | $-28.8M | ||
| Q2 24 | $-36.5M | $-22.7M | ||
| Q1 24 | $-46.6M | $-31.2M |
| Q4 25 | -77.7% | -60.5% | ||
| Q3 25 | -196.6% | -121.6% | ||
| Q2 25 | -244.1% | -103.2% | ||
| Q1 25 | -163.5% | -164.3% | ||
| Q4 24 | -191.8% | -138.8% | ||
| Q3 24 | -197.4% | -204.4% | ||
| Q2 24 | -170.5% | -134.6% | ||
| Q1 24 | -188.3% | -192.1% |
| Q4 25 | — | -64.1% | ||
| Q3 25 | -260.1% | -123.6% | ||
| Q2 25 | -313.2% | -99.7% | ||
| Q1 25 | -221.8% | -151.7% | ||
| Q4 24 | — | -131.4% | ||
| Q3 24 | -244.1% | -197.3% | ||
| Q2 24 | -214.6% | -126.1% | ||
| Q1 24 | -261.1% | -182.7% |
| Q4 25 | $0.04 | $-0.42 | ||
| Q3 25 | $-0.30 | $-0.88 | ||
| Q2 25 | $-0.50 | $-0.85 | ||
| Q1 25 | $-0.36 | $-1.06 | ||
| Q4 24 | $-0.26 | $-1.05 | ||
| Q3 24 | $-0.42 | $-1.36 | ||
| Q2 24 | $-0.38 | $-1.07 | ||
| Q1 24 | $-0.56 | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $261.3M | $37.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-185.8M | $126.6M |
| Total Assets | $323.1M | $329.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $261.3M | $37.4M | ||
| Q3 25 | $234.7M | $32.3M | ||
| Q2 25 | $264.6M | $44.8M | ||
| Q1 25 | $194.7M | $60.2M | ||
| Q4 24 | $250.9M | $84.3M | ||
| Q3 24 | $274.3M | $37.2M | ||
| Q2 24 | $300.1M | $35.8M | ||
| Q1 24 | $234.3M | $63.5M |
| Q4 25 | $-185.8M | $126.6M | ||
| Q3 25 | $-238.2M | $64.7M | ||
| Q2 25 | $-199.2M | $79.3M | ||
| Q1 25 | $-238.2M | $93.5M | ||
| Q4 24 | $-202.6M | $111.8M | ||
| Q3 24 | $-171.9M | $128.8M | ||
| Q2 24 | $-131.7M | $148.9M | ||
| Q1 24 | $-194.4M | $166.1M |
| Q4 25 | $323.1M | $329.5M | ||
| Q3 25 | $289.8M | $280.7M | ||
| Q2 25 | $321.6M | $301.0M | ||
| Q1 25 | $272.5M | $323.0M | ||
| Q4 24 | $322.0M | $348.6M | ||
| Q3 24 | $349.1M | $376.7M | ||
| Q2 24 | $371.8M | $398.8M | ||
| Q1 24 | $308.0M | $413.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.1M | $-11.7M |
| Free Cash FlowOCF − Capex | — | $-11.8M |
| FCF MarginFCF / Revenue | — | -63.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-18.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.1M | $-11.7M | ||
| Q3 25 | $-29.6M | $-6.5M | ||
| Q2 25 | $-24.1M | $17.5M | ||
| Q1 25 | $-56.3M | $-13.5M | ||
| Q4 24 | $-21.9M | $-16.8M | ||
| Q3 24 | $-25.0M | $-10.4M | ||
| Q2 24 | $-32.8M | $-14.8M | ||
| Q1 24 | $-44.1M | $-28.6M |
| Q4 25 | — | $-11.8M | ||
| Q3 25 | — | $-7.9M | ||
| Q2 25 | — | $17.4M | ||
| Q1 25 | $-56.6M | $-16.0M | ||
| Q4 24 | $-21.9M | $-25.5M | ||
| Q3 24 | $-25.3M | $-19.4M | ||
| Q2 24 | $-32.9M | $-21.3M | ||
| Q1 24 | $-44.6M | $-30.3M |
| Q4 25 | — | -63.6% | ||
| Q3 25 | — | -52.5% | ||
| Q2 25 | — | 94.7% | ||
| Q1 25 | -325.2% | -107.4% | ||
| Q4 24 | -129.8% | -150.6% | ||
| Q3 24 | -140.2% | -132.5% | ||
| Q2 24 | -193.0% | -118.6% | ||
| Q1 24 | -250.0% | -177.5% |
| Q4 25 | 0.0% | 0.8% | ||
| Q3 25 | 0.0% | 9.6% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 1.5% | 17.0% | ||
| Q4 24 | 0.5% | 51.6% | ||
| Q3 24 | 1.2% | 61.3% | ||
| Q2 24 | 0.2% | 36.4% | ||
| Q1 24 | 3.0% | 9.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
